Central Nervous System Myeloma and New Drugs: Can we Begin the Fight?

Authors

  • Alessandro Gozzetti Azienda Ospedaliera Universitaria Senese

DOI:

https://doi.org/10.15379/2408-9877.2014.01.02.1

Keywords:

Extramedullary myeloma, chemotherapy, CNS, bortezomib, IMID’s, new agents

Abstract

Editorial

Author Biography

Alessandro Gozzetti, Azienda Ospedaliera Universitaria Senese

Hematology

References

Kyle RA, Rajkumar SV Multiple Myeloma. Blood 2008; 11: 2962-72.

Brenner H, Gondos A, Pulte D Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–26.

Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–20.

Cerase A, Tarantino A, Gozzetti A, Muccio CF, Gennari P, et al. Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay. Neuroradiology 2008; 50 :665-74.

Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, et al. Extramedullary intracranial localizations of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 2012; 118: 1574-84.

Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol 2012; 69: 943-7.

Petersen S, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999;62: 228–33.

Knight R IMiDs: a novel class of immunomodulators. Semin Oncol 2005; 32:24-30.

Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011; 25: 906-8.

Mussetti A, Dalto S, Montefusco V Effective treatment of pomalidomide in central nervous system myelomatosis. Leuk Lymphoma 2013; 54:864-6.

Richardson, P.G., Spencer, A., Cannell, P., Harrison, S.J., Catley, L., et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2011; 118: 302.

Downloads

Published

2014-11-20

Issue

Vol. 1 No. 2 (2014)

Section

Articles

License

Policy for Journals/Articles with Open Access

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work

Policy for Journals / Manuscript with Paid Access

Authors who publish with this journal agree to the following terms:
    1. Publisher retain copyright .

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .